[April 23, 2014] |
|
Research and Markets: Global Peripheral T-Cell Lymphomas (PTCL) Therapeutics Pipeline Review 2014 - Analysis of 12 Companies & 22 Drug Profiles
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/shhbg8/peripheral_tcell)
has announced the addition of the "Peripheral
T-Cell Lymphomas (PTCL) - Pipeline Review, H1 2014" report to
their offering.
This report provides comprehensive information on the therapeutic
development for Peripheral T-Cell Lymphomas (PTCL), complete with
comparative analysis at various stages, therapeutics assessment by drug
target, mechanism of action (MoA), route of administration (RoA) and
molecule type, along with latest updates, and featured news and press
releases. It also reviews key players involved in the therapeutic
development for Peripheral T-Cell Lymphomas (PTCL) and special features
on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create
effective counter strategies to gain competitive advantage. It
strengthens R&D pipelines by identifying new targets and MOAs to produce
first-in-class and best-in-class products.
Scope
-
The report provides a snapshot of the global therapeutic landscape o
Peripheral T-Cell Lymphomas (PTCL)
-
The report reviews key pipeline products under drug profile section
which includes, product description, MoA and R&D brief, licensing and
collaboration details & other developmental activities
-
The report reviews key players involved in the therapeutics
development for Peripheral T-Cell Lymphomas (PTCL) and enlists all
their major and minor projects
-
The report summarizes all the dormant and discontinued pipeline
projects
-
A review of the Peripheral T-Cell Lymphomas (PTCL) products under
development by companies and universities/research institutes based on
information derived from company and industry-specific sources
-
Pipeline products coverage based on various stages of development
ranging from pre-registration till discovery and undisclosed stages
-
A detailed assessment of monotherapy and combination therapy pipeline
projects
-
Coverage of the Peripheral T-Cell Lymphomas (PTCL) pipeline on the
basis of target, MoA, route of administration and molecule type
-
Latest news and deals relating related to pipeline products
Companies Involved in Therapeutics Development
-
Kyowa Hakko Kirin Co., Ltd.
-
ZIOPHARM Oncology, Inc.
-
Millennium Pharmaceuticals, Inc.
-
Eisai Co., Ltd.
-
Celgene Corporation
-
Incyte Corporation
-
Topotarget A/S
-
Mundipharma International Limited
-
Spectrum (News - Alert) Pharmaceuticals, Inc.
-
Chipscreen Biosciences Ltd
-
CerRx, Inc.
-
Rhizen Pharmaceuticals SA
Drug Profiles
-
belinostat
-
mogamulizumab
-
pralatrexate
-
pralatrexate
-
romidepsin
-
alisertib
-
pralatrexate
-
romidepsin
-
HBI-8000
-
belinostat
-
mogamulizumab
-
ruxolitinib phosphate
-
darinaparsin
-
romidepsin
-
fenretinide
-
forodesine hydrochloride
-
pralatrexate
-
darinaparsin
-
denileukin diftitox
-
alefacept
-
TGR-1202
-
darinaparsin
For more information visit http://www.researchandmarkets.com/research/shhbg8/peripheral_tcell
[ Back To TMCnet.com's Homepage ]
|